Dr. Lechner’s research interests are related to understanding the cause of immune related adverse events (IrAE) from cancer immunotherapy. Using a novel mouse model of immune checkpoint inhibitor (ICI)-IrAE that she developed, Dr. Lechner is identifying key drivers of these unwanted autoimmune toxicities and evaluating new therapeutic approaches that reduce toxicity without decreasing the anti-tumor efficacy of immunotherapy. In addition, she established the Onco-Endocrinology clinic at UCLA to care for patients with endocrine side effects from cancer immunotherapy, leads prospective clinical trials at UCLA in patients with ICI-associated IrAE, and serves on the National Comprehensive Cancer Network Management of Immunotherapy Toxicity Side Effects guidance panel.
Lechner MG, Vyas C, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced non-thyroid cancer patients. Thyroid. 2018 Apr;28(4):437-444. PMID: 29652599
Lechner MG, Vyas C, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced non-thyroid cancers. Thyroid. 2018 Apr;28(4):445-453. PMID: 29652597
Lechner MG, Bernardo AC, Lampe A, Smooke Praw S, Tam S, Angell TE. Comparison of Stage Distribution and Disease Specific Survival in Differentiated Thyroid Cancer between AJCC 7th and 8th editions: A Systematic Review and Meta-Analysis. The Oncologist. 2020, Aug 30;26(2):e251-60. PMID: 3286432
Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, In GK, Su MA, Lechner MG. COVID-19 Outcomes of Patients with Differentiated Thyroid Cancer: A Multi-Center Los Angeles Cohort Study. Endocrine Practice, 2021 Feb;27(2):90-94. PMID: 33551317
Schumm M, Lechner MG, Shu ML, Ochoa JE, Kim J, Tseng C, Leung AM, Yeh MW. Frequency of Thyroid Hormone Replacement after Lobectomy for Differentiated Thyroid Cancer. Endocrine Practice, in press. DOI:https://doi.org/10.1016/j.eprac.2021.01.004